000153630 001__ 153630 000153630 005__ 20251017144554.0 000153630 0247_ $$2doi$$a10.1016/j.adengl.2020.01.009 000153630 0248_ $$2sideral$$a116823 000153630 037__ $$aART-2020-116823 000153630 041__ $$aspa 000153630 100__ $$aCarrascosa, J. M. 000153630 245__ $$aEstudio Delphi para el uso de apremilast en psoriasis 000153630 260__ $$c2020 000153630 5060_ $$aAccess copy available to the general public$$fUnrestricted 000153630 5203_ $$aBackground: Experience in the use of apremilast in clinical practice complements the information available from pivotal clinical trials. Materials and methods: Following a review of the literature, a panel of dermatologists with expertise in the management of psoriasis considered 5 scenarios in which the evidence supporting the use of apremilast to treat moderate psoriasis is insufficient or controversial. These scenarios were then assessed using a Delphi questionnaire. Results: Consensus was reached on 96 (67%) of the 143 items (positive in 85 and negative in 11). The therapeutic goal for apremilast should be based on 4 outcomes: clinical response, symptoms, quality of life, and patient satisfaction. The scenario in which the use of apremilast was considered to have the greatest possibility of success was in patients with stable moderate psoriasis. Most of the clinicians considered apremilast to be an appropriate treatment when conventional therapies fail or are contraindicated, preferably before the prescription of biologic therapy. Consensus was reached that apremilast is an appropriate treatment for psoriasis in difficult locations, such as the scalp or the palms and soles. It was also agreed that apremilast requires less prescreening and monitoring than other conventional and biologic systemic therapies. Conclusions: Apremilast could be a treatment option for patients with a different profile to that of clinical trial participants. The limitations of this proposal are the absence of consensus on the definition of moderate psoriasis, the lack of real-world evidence on the use of apremilast, and certain aspects related to tolerability. 000153630 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es 000153630 592__ $$a0.272$$b2020 000153630 593__ $$aDermatology$$c2020$$dQ3 000153630 593__ $$aPathology and Forensic Medicine$$c2020$$dQ3 000153630 593__ $$aHistology$$c2020$$dQ3 000153630 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000153630 700__ $$aBelinchón, I. 000153630 700__ $$aRivera, R. 000153630 700__ $$0(orcid)0000-0001-8789-6783$$aAra, M.$$uUniversidad de Zaragoza 000153630 700__ $$aBustinduy, M. 000153630 700__ $$aHerranz, P. 000153630 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología 000153630 773__ $$g111, 2 (2020), 115-134$$pActas dermo-sifiliogr.$$tActas Dermo-Sifiliograficas$$x0001-7310 000153630 85641 $$uhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85078822839&doi=10.1016%2fj.adengl.2020.01.009&partnerID=40&md5=aa391575d519b04fb2897d1a61968479$$zTexto completo de la revista 000153630 8564_ $$s574266$$uhttps://zaguan.unizar.es/record/153630/files/texto_completo.pdf$$yVersión publicada 000153630 8564_ $$s2218425$$uhttps://zaguan.unizar.es/record/153630/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000153630 909CO $$ooai:zaguan.unizar.es:153630$$particulos$$pdriver 000153630 951__ $$a2025-10-17-14:12:34 000153630 980__ $$aARTICLE